Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
Epistemonikos ID: 15e035be7b4b530a0ef23a8b0ce60d97d7e4f631
First added on: Feb 24, 2026